A double bottom line doesn't have to mean half the profits

May 13, 2010 by MassDevice

Nanobiosym CEO Dr. Anita Goel on how humanitarian-focused businesses can have big profits in the long run.

World Health Medical Technology Conference logo

MassDevice.com is blogging on the topic of building innovative medical technology for the developing world, featuring some of the leading minds in the field.

This feature will continue through May 17 and the first annual World Health Medical Technology Conference at Boston University.

The conference is a one-day workshop dedicated to exploring the opportunities and challenges of designing, building and funding medical technologies for the developing world. It's a way to bring together stakeholders from the medical technology industry with the leading minds in the Global Health movement. To find out more about the conference, visit the conference's website for an agenda, registration information and a list of speakers.

This installment features Dr. Anita Goel, CEO of Nanobiosym, a stealthy incubator and diagnostics company working on technologies at the convergence point of physics, nanotechnology and biomedicine. Goel is one of the most respected voices in science and business and her vision of changing the world with innovation are probably only matched by her board of directors, which includes Boston Scientific Corp. (NYSE:BSX) founder John Abele; Ratan Tata, chairman of the Tata Group, one of the largest conglomerates in India; Alfred Ford, the current chairman of the Ford Motor Co. (NYSE:F) and grandson of Henry Ford; and former Ambassador John Palmer.

The company is primarily funded by government contracts from agencies including the Defense Advanced Research Projects Agency, the Air Force Office of Scientific Research and the U.S. Dept. of Energy.

Dr. Goel took a few minutes to talk about her views on the developing world and how diagnostics can be made not only cheaper but more accurate.

Anita Goel

Dr. Anita Goel, CEO, Nanobiosym